Nasu Ryo

Affiliation and department：
Job title：特任助教

Research field (2)： Immunology , Tumor biology

Research keywords (3)：がん免疫 , cancer stem cells , glioblastoma

Research theme for competitive and other funds (11)：

Show all

Papers (26)：

Ayaka Hara, Ryo Koyama-Nasu, Mariko Takami, Takahide Toyoda, Takahiro Aoki, Fumie Ihara, Masayoshi Kobayashi, Seiichiro Hirono, Tomoo Matsutani, Toshinori Nakayama, et al. CD1d expression in glioblastoma is a promising target for NKT cell-based cancer immunotherapy. Cancer Immunology, Immunotherapy. 2020
Ryutaro Kotaki, Masaharu Kawashima, Asuka Yamaguchi, Naoto Suzuki, Ryo Koyama-Nasu, Daisuke Ogiya, Kazuki Okuyama, Yuichiro Yamamoto, Masako Takamatsu, Natsumi Kurosaki, et al. Overexpression of miR-669m inhibits erythroblast differentiation. Scientific reports. 2020. 10. 1. 13554-13554
Akane S. Suzuki, Ryoji Yagi, Motoko Y. Kimura, Chiaki Iwamura, Kenta Shinoda, Atsushi Onodera, Kiyoshi Hirahara, Damon J. Tumes, Ryo Koyama-Nasu, Siiri E. Iismaa, et al. Essential Role for CD30-Transglutaminase 2 Axis in Memory Th1 and Th17 Cell Generation. Frontiers in Immunology. 2020. 11
Takahiro Aoki, Mariko Takami, Tomozumi Takatani, Kiwamu Motoyoshi, Ayana Ishii, Ayaka Hara, Takahide Toyoda, Reona Okada, Moeko Hino, Ryo Koyama-Nasu, et al. Activated invariant natural killer T cells directly recognize leukemia cells in a CD1d-independent manner. Cancer Science. 2020
Kimura MY, Koyama-Nasu R, Yagi R, Nakayama T. A new therapeutic target: the CD69-Myl9 system in immune responses. Seminars in Immunopathology. 2019. 41. 3. 349-358

ｍore...

MISC (13)：

ｍore...

Books (2)：

Lectures and oral presentations (27)：

CD1d expression in glioblastoma is a promising target for NKT cell-based cancer immunotherapy
(第78回日本癌学会学術総会 2019)
CD1d expression in glioblastoma is a promising target for NKT cell-based cancer immunotherapy
(EMBO workshop CD1-MR1 2019)
Inhibition of acetyl-CoA carboxylase enhances memory Th2 cell generation and Th2 mediated anti-tumor immunity
(第23回日本がん免疫学会総会 2019)
膠芽腫に発現するCD1d 分子はNKT 細胞を用いた免疫療法における有望な標的となる
(第23回日本がん免疫学会総会 2019)
がん免疫療法の新たなターゲットとしてのCD69の可能性
(第23回日本がん免疫学会総会 2019)

ｍore...

Education (2)：

Professional career (1)：

Work history (6)：

2016 - 現在 Chiba University Graduate School of Medicine
2015 - Tokai University School of Medicine
2013 - Kyoto Prefectural University of Medicine Graduate School of Medical Science
2007 - The University of Tokyo Institute of Molecular and Cellular Biosciences
2003 - ニューヨーク大学医学部博士研究員

Show all

Committee career (2)：

Association Membership(s) (2)：

THE JAPANESE SOCIETY FOR IMMUNOLOGY , THE JAPANESE CANCER ASSOCIATION

※ Researcher’s information displayed in J-GLOBAL is based on the information registered in researchmap. For details, see here.

Return to Previous Page